ATXS
Price
$5.14
Change
-$0.38 (-6.88%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
311.52M
34 days until earnings call
ZYME
Price
$11.77
Change
-$0.15 (-1.26%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
818.92M
Ad is loading...

ATXS vs ZYME

Header iconATXS vs ZYME Comparison
Open Charts ATXS vs ZYMEBanner chart's image
Astria Therapeutics
Price$5.14
Change-$0.38 (-6.88%)
Volume$6.45K
Capitalization311.52M
Zymeworks
Price$11.77
Change-$0.15 (-1.26%)
Volume$99.89K
Capitalization818.92M
ATXS vs ZYME Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. ZYME commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and ZYME is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ATXS: $5.52 vs. ZYME: $11.77)
Brand notoriety: ATXS and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 94% vs. ZYME: 200%
Market capitalization -- ATXS: $311.52M vs. ZYME: $818.92M
ATXS [@Biotechnology] is valued at $311.52M. ZYME’s [@Biotechnology] market capitalization is $818.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while ZYME’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • ZYME’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than ZYME.

Price Growth

ATXS (@Biotechnology) experienced а -9.66% price change this week, while ZYME (@Biotechnology) price change was -5.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

ATXS is expected to report earnings on May 08, 2025.

ZYME is expected to report earnings on May 08, 2023.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZYME($819M) has a higher market cap than ATXS($312M). ZYME YTD gains are higher at: -19.604 vs. ATXS (-38.255). ZYME (-108.62M) and ATXS (-111.56M) have comparable annual earnings (EBITDA) . ATXS has more cash in the bank: 328M vs. ZYME (226M). ATXS has less debt than ZYME: ATXS (5.35M) vs ZYME (18.5M). ZYME has higher revenues than ATXS: ZYME (76.3M) vs ATXS (0).
ATXSZYMEATXS / ZYME
Capitalization312M819M38%
EBITDA-111.56M-108.62M103%
Gain YTD-38.255-19.604195%
P/E RatioN/AN/A-
Revenue076.3M-
Total Cash328M226M145%
Total Debt5.35M18.5M29%
FUNDAMENTALS RATINGS
ATXS vs ZYME: Fundamental Ratings
ATXS
ZYME
OUTLOOK RATING
1..100
8277
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
9262
P/E GROWTH RATING
1..100
10059
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZYME's Valuation (48) in the Pharmaceuticals Major industry is in the same range as ATXS (63) in the Biotechnology industry. This means that ZYME’s stock grew similarly to ATXS’s over the last 12 months.

ZYME's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ATXS (100) in the Biotechnology industry. This means that ZYME’s stock grew similarly to ATXS’s over the last 12 months.

ZYME's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as ATXS (97) in the Biotechnology industry. This means that ZYME’s stock grew similarly to ATXS’s over the last 12 months.

ZYME's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as ATXS (92) in the Biotechnology industry. This means that ZYME’s stock grew similarly to ATXS’s over the last 12 months.

ZYME's P/E Growth Rating (59) in the Pharmaceuticals Major industry is somewhat better than the same rating for ATXS (100) in the Biotechnology industry. This means that ZYME’s stock grew somewhat faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSZYME
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 15 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HIMCX26.39N/A
N/A
Hartford MidCap HLS IA
AUERX12.85N/A
N/A
Auer Growth
WFGDX9.82N/A
N/A
Allspring Emerging Growth Admin
MIGDX30.20N/A
N/A
MFS Massachusetts Inv Gr Stk C
VKSAX19.57N/A
N/A
Virtus KAR Small-Mid Cap Core A

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+2.22%
KYMR - ATXS
50%
Loosely correlated
+4.46%
DNLI - ATXS
48%
Loosely correlated
+11.80%
TRDA - ATXS
48%
Loosely correlated
+0.46%
ABOS - ATXS
47%
Loosely correlated
+0.47%
IMNM - ATXS
46%
Loosely correlated
+7.19%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with KYMR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
-1.26%
KYMR - ZYME
44%
Loosely correlated
-10.13%
ATXS - ZYME
42%
Loosely correlated
-6.61%
CCCC - ZYME
41%
Loosely correlated
-9.87%
DNLI - ZYME
41%
Loosely correlated
-6.91%
KURA - ZYME
40%
Loosely correlated
-5.21%
More